He START Center for Cancer Research Doses First U.S. Patient in Moderna's Phase 1 Clinical Trial of mRNA-4106, A Pan-Tumor Antigen Therapy Candidate, in Solid Tumors

Published: 2025-05-15 09:50:39 ET MRNA

Published on 05/15/2025 at 09:50

The START Center for Cancer Research announced the dosing of the first U.S. participant in Moderna 's Phase 1 study evaluating mRNA-4106, a novel Pan-Tumor Antigen Therapy candidate, in patients with advanced or metastatic solid tumors. The Phase 1 trial will evaluate the safety, pharmacodynamics, immunogenicity and preliminary efficacy of mRNA-4106 administered alone and in combination with checkpoint inhibitor therapy. mRNA-4106's multivalent approach aims to broaden treatment options for patients with cancer, advancing the field beyond single-targeted immunotherapies.